How peptide reserves are calculated and negotiated
- Peptide reserves are the acquirer's cushion against your future chargebacks and refunds, commonly 10-15% rolling held 180 days in year one.
- A rolling reserve withholds a percentage of every batch and releases it on a delay; an upfront reserve takes a lump sum at onboarding, and the structure is negotiable even when the rate is not.
- You earn a reduction with demonstrated history, not a phone call, and your first 90 days set the baseline the reviewer measures you against.
On this page
You signed at 4.0% effective and felt good about it. Then the first payout landed and 15% of it wasn't there. Nobody stole it — it's sitting in a reserve account, and it'll keep sitting there for 180 days before the first dollar comes back to you. For a peptide operator running on thin working capital, the reserve is often a bigger cash-flow problem than the rate, and it's the part of the deal most operators never think to negotiate. This is how the number gets set, and how you move it.
What a reserve actually is
A reserve is the acquirer's cushion against money they might have to pay back on your behalf — chargebacks, refunds, and fees that hit after you've already been paid and possibly already spent it. When a customer disputes a charge from 60 days ago, the acquirer is on the hook to return those funds whether or not you still have them. The reserve is how they make sure they do.
For peptides the reserve runs higher than for plain ecommerce because the risk is higher: declining-bank verticals, elevated chargeback potential, and regulatory exposure. The acquirer isn't punishing you. They're pricing the probability that they'll have to cover something later, and peptides carry more of that probability than a coffee brand does.
It helps to separate the reserve from the rate in your head, because they answer different questions. The rate is what the acquirer charges to run your transactions. The reserve is what the acquirer holds back in case those transactions come back. You pay the rate; you don't pay the reserve — it's your money, held and released on a schedule. That distinction is why a reserve feels worse than a rate even when it costs less in the end: a rate is a known expense, but a reserve is your own working capital, frozen for months before it trickles back. Understanding it as a timing problem rather than a cost problem changes how you negotiate it.
Rolling vs upfront: the two structures
There are two ways an acquirer holds your reserve, and the difference matters for your cash flow.
A rolling reserve withholds a fixed percentage of every settlement batch and releases each piece on a delay — typically 90 to 180 days after it was held. It builds up, plateaus once the oldest funds start releasing, then runs as a steady-state cushion. Most peptide accounts use this structure.
An upfront reserve takes a lump sum at onboarding — sometimes funded from your first batches, sometimes required as a deposit — and holds it for the life of the account or until a review. It hurts more on day one but stops withholding from ongoing batches once it's funded. The rolling-vs-upfront breakdown compares the cash-flow curves directly.
Which one you get is part of the offer, and it is negotiable. An operator with tight working capital and clean history can sometimes trade a higher rolling percentage for no upfront lump sum, or vice versa.
The year-one peptide math
Across specialist ISOs, first-year peptide reserves cluster in a predictable band. Here is the typical range and what moves you within it.
| Profile | Reserve % | Hold period | Structure |
|---|---|---|---|
| Clean history, 4+ mo statements | 10% | 180 days | Rolling |
| Typical year-one peptide | 10-15% | 180 days | Rolling |
| New operator, no history | 15% | 180 days | Rolling |
| Post-closure / elevated chargebacks | 15-20% | 180 days | Rolling or upfront |
| Established, 12+ mo clean | 5-10% | 90-180 days | Rolling |
The general market range is 5-20% rolling, held 90-180 days. Peptide year-one lands at 10-15% rolling for 180 days for most operators. A new brand with no processing history sits at the top of the band; an operator bringing four clean months of statements sits at the bottom. The reserve and the rate are set by the same underwriting file, so the work that lowers one tends to lower both — the underwriting review is where that file gets read.
What actually drives your reserve up or down
The reserve number is a function of a few specific inputs. Knowing them tells you where to apply effort before you apply.
- Chargeback ratio and trend. The single biggest driver. A ratio under 0.6% and falling pulls the reserve down; one near or over the network ceilings (Visa VAMP 0.9%, Mastercard ECM 1.0%) pushes it up.
- Reason-code mix. Product-quality and not-as-described disputes signal repeat risk and raise the hold more than fraud disputes do.
- Processing history. Three-plus months of clean statements is the difference between the top and bottom of the band. No history means top of band.
- Refund behavior. A visible, proactive refund rate reads as risk control and helps. Near-zero refunds beside high disputes reads as the opposite.
- Ticket size and volume smoothness. Large average tickets and spiky volume both raise the cushion the acquirer wants.
None of these is the peptide itself. They're all things you control in the 90 days before and after you apply.
The reserve nobody warned you about: Stripe's
Operators coming off a Stripe freeze often think a reserve is a high-risk-acquirer thing. It isn't. Stripe holds peptide funds too — it just doesn't call it a negotiated reserve, and you don't find out until the funds-hold email arrives. A Stripe review can park 90-180 days of funds with no schedule you agreed to and no review cadence you can plan around, because peptides violate its acceptable use policy in the first place. That is the worst of both worlds: a hold as heavy as a high-risk reserve, with none of the predictability. A specialist acquirer's reserve is at least a known quantity — a stated percentage, a stated hold, a stated review date. If you are comparing the trapped capital of a Stripe hold against a structured peptide reserve, the Stripe comparison for peptides lays the two side by side. A negotiated reserve you can see beats an undisclosed hold you can't.
How to negotiate the reserve
Operators negotiate the rate and forget the reserve is on the table too. It is, and the lever is evidence, not persuasion.
At signing
Bring statements. Three-plus clean months gives you standing to ask for the bottom of the band rather than the default. Ask explicitly whether the structure can flex — a lower upfront in exchange for a slightly higher rolling, or a shorter hold period. Get the reserve percentage, hold period, and review cadence in writing before you sign, alongside any setup fee and ETF.
At the review
Reserves are reviewed, usually at 6 and 12 months. A reduction is earned with demonstrated history: a chargeback ratio that fell and stayed down, a quiet reason-code mix, and steady volume. Come to the review with the numbers, not a request. The reserve-release guide walks the exact case to make and when to make it.
The thing you can't shortcut is your first 90 days. They set the baseline the reviewer measures everything against. A clean launch is the highest-leverage reserve negotiation you'll ever run, and it happens before you ever ask.
What a reserve actually costs you
The reserve percentage is easy to read as an abstract number, so it helps to put it in working-capital terms. Take an operator doing $200,000 a month at a 15% rolling reserve held 180 days. Once the reserve fully ramps, roughly $180,000 of capital is sitting in the reserve account at any given time — six months of withheld funds before the oldest dollars start releasing back. That is real money you can't put into inventory, ad spend, or payroll.
This is why the structure and the percentage are worth fighting for, not just the rate. Shaving a reserve from 15% to 10% on that same volume frees about $60,000 of standing capital once ramped. Shortening the hold from 180 to 90 days roughly halves the time each dollar is trapped. Those moves often do more for your cash position than a 30-basis-point rate cut ever would, which is exactly why operators who only negotiate the rate leave the bigger lever on the table. Model the reserve as trapped capital, then decide where to push.
Reserves across a multi-brand portfolio
Run several peptide brands on separate merchant accounts and you carry a separate reserve on each — separate percentages, separate hold clocks, separate release dates. Capital sits trapped in N reserve accounts, and adding a brand means funding another one from scratch.
A parent account consolidates the reserve into one relationship with one history and one release schedule, which can free working capital that would otherwise sit spread across accounts. multiflow orchestrates that parent-account model on top of your acquirer — we coordinate the structure and the ledger, we don't hold the reserve or process the charge ourselves. And we don't onboard single-brand operators; one brand belongs on a specialist ISO. Whether consolidation actually frees capital for you depends on brand count and your current reserve spread, and the peptide operator playbook has the tradeoffs.
What to do before you sign
Know your chargeback ratio and reason-code mix. Export three or more months of statements. Ask for the reserve and the rate as two separate negotiations, and get the structure, percentage, hold, and review cadence in writing. Then protect your first 90 days like they set your terms for the year — because they do.
If you're running multiple peptide brands and your working capital is trapped across separate reserve accounts, talk to an underwriter about whether a parent-account structure frees it up. Twelve questions, no hard pull, and an honest answer — including "your current spread is fine" when it is.